Adaptin Bio, Inc. Common Shares Approved for Quotation on OTCQB; Lead Therapeutic to Enter Clinical Trials

Key Highlights for Investors

• Adaptin Bio, Inc. (OTCQB: APTN) has received approval for its common shares to be quoted on the OTCQB Venture Market under ticker symbol APTN.
• Trading is expected to begin within the next 6-8 weeks, potentially enhancing liquidity and visibility among U.S. investors.
• The company’s lead program, APTN-101, is poised to enter a Phase 1 first-in-human clinical trial targeting glioblastoma (GBM), a highly aggressive brain cancer.
• APTN-101 leverages Adaptin’s proprietary BRiTE antibody delivery platform and has demonstrated compelling anti-tumor activity and a favorable safety profile in multiple preclinical models.
• The BRiTE platform and APTN-101 are designed to address central nervous system (CNS)-targeted therapies for difficult-to-treat cancers, representing a significant unmet medical need.
• APTN-101 is FDA-cleared for Phase 1 clinical trials in glioblastoma, and additional indications are being considered for future studies.

In-Depth Company and Product Overview

Adaptin Bio, Inc., based in Charlotte, N.C., is a biotechnology company focused on developing precision oncology therapeutics, particularly for cancers affecting the brain and other challenging tissues. The company’s mission is to improve outcomes for patients facing difficult-to-treat cancers by leveraging novel delivery technologies.

APTN-101 is a brain bispecific T cell engager that utilizes the company’s proprietary BRiTE platform. This technology manipulates immune cells to effectively “hitchhike” therapeutic agents directly to brain tumors, thereby overcoming traditional barriers to drug delivery in the CNS. Preclinical studies have shown that APTN-101:

• Has high specificity for EGFRvIII-expressing glioma cells
• Demonstrates dose-responsive efficacy against a range of patient-derived glioma cell lines
• Presents a favorable safety profile

By targeting EGFRvIII, a mutation commonly associated with aggressive gliomas, Adaptin’s approach represents a potentially transformative therapy for patients with limited existing treatment options.

Potential Price-Sensitive Information for Shareholders

• OTCQB Quotation Approval: The approval to quote shares on the OTCQB is a significant milestone. This can attract new investors, improve liquidity, and enhance overall market visibility, potentially impacting share value positively as the company transitions to a more accessible trading platform.
• Near-Term Clinical Milestone: The imminent initiation of a Phase 1 clinical trial for APTN-101 is a key inflection point. Clinical progress, especially in first-in-human studies for high-need indications like GBM, is typically viewed as a major catalyst by the investment community.
• Innovative Technology Platform: The BRiTE bispecific T cell engager platform’s ability to target brain tumors through enhanced immune cell delivery could position Adaptin Bio as a leader in next-generation CNS cancer therapeutics, drawing interest from both strategic partners and institutional investors.
• Regulatory and Pipeline Updates: APTN-101 is FDA-cleared for Phase 1 trials in GBM, with the company exploring other indications. Any further regulatory progress or expansion of indications could further influence share prices.

Risks and Forward-Looking Statements

While the company’s recent achievements are promising, several risks remain that could impact future performance and share value. These include:

• The necessity to secure additional funding to support operations over the next 12 months
• Potential delays, costs, and uncertainties related to clinical trials and regulatory approvals
• The need to attract, retain, and integrate qualified personnel and maintain corporate culture
• Risks related to intellectual property, third-party manufacturing, and supply chain logistics
• General market volatility and changes in the regulatory environment

Shareholders should monitor upcoming announcements regarding trading commencement, clinical trial initiation, and any updates on regulatory or pipeline progress, as these could materially affect valuation and investment outlook.

Contact Information

Investor Contact:
1-800-428-8070
[email protected]
www.adaptinbio.com

Disclaimer: This article is for informational purposes only and is not intended as investment advice. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those described. Investors should conduct their own due diligence and consult a financial advisor before making investment decisions. Adaptin Bio, Inc. assumes no obligation to update forward-looking statements except as required by law.

View ADAPTIN BIO, INC. Historical chart here